Recent Updates — LENZ

LENZ Therapeutics announced a strategic reorganization to prioritize consumer marketing and reduce operating expenses, including decreasing its workforce by approximately 75% to about 40 full-time employees. The company expects to incur non-recurring charges of approximately $5 million for severance and related benefits, substantially all in the fourth quarter of 2026. Concurrently, President and CEO Eef Schimmelpennink will transition from his roles effective December 1, 2026, with CFO Daniel Chevallard appointed as Interim President and CEO. The filing also reported third-quarter product sales of $2.6 million, a 50% increase over the prior quarter. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ for presbyopia.

LENZ Therapeutics reported second quarter 2026 financial results on August 11, 2026. Total revenue was $5.5 million, comprising $1.7 million in product sales from approximately 27,000 packs of VIZZ and $3.8 million in license revenue, which included a $2.5 million regulatory milestone under the Théa agreement and $1.25 million in sublicense revenue from Everest Medicines for Greater China rights. The company reported a net loss of $31.9 million, or $1.02 per share, compared to a $14.9 million loss in the prior year period. Selling, general, and administrative expenses rose to $39.4 million due to launch investments in marketing and sales infrastructure. Cash, cash equivalents, and marketable securities totaled $220.0 million as of June 30, 2026. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ for the treatment of presbyopia.

Zach Scheiner resigned from the Board of Directors and all its committees effective June 30, 2026, without any disagreement with the Company. The Board size was subsequently reduced to six members, and Jeff George was appointed to the Audit Committee. LENZ Therapeutics, Inc. is a biotechnology company focused on ophthalmic therapies.